Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mattia Cremona
Observed names:
Cremona, Mattia,
M Cremona,
M. Cremona,
M. Laura Cremona
Institution:
Royal College of Surgeons in Ireland
Observed institutions:
Royal College of Surgeons in Ireland,
University of California, Los Angeles,
George Mason University,
Beaumont Hospital,
St. Vincent's University Hospital,
Fondazione IRCCS Istituto Nazionale dei Tumori,
Dublin City University,
University of Palermo
show all 8
ORCID:
0000-0003-3000-6246
Observed ORCID:
0000-0003-3000-6246
OpenAlex ID:
A5046521768
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing
2015
·
Lisa R. Susswein
, Megan L. Marshall
, et al.
·
Genetics in Medicine
·
323
PDF
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
2013
·
Britta Stordal
, Kirsten Timms
, et al.
·
Molecular Oncology
·
181
PDF
BCL-2 system analysis identifies high-risk colorectal cancer patients
2016
·
Andreas U Lindner
, Manuela Salvucci
, et al.
·
Gut
·
57
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
2014
·
N. Elster
, M. Cremona
, et al.
·
Breast Cancer Research and Treatment
·
52
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
2019
·
Marta Llaurado Fernandez
, Amy Dawson
, et al.
·
Cancer Cell International
·
48
PDF
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
2021
·
M. Janusz Mezynski
, Angela M. Farrelly
, et al.
·
Journal of Translational Medicine
·
47
PDF
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
2020
·
Alexandra Canonici
, Alacoque L. Browne
, et al.
·
Therapeutic Advances in Medical Oncology
·
38
Bsx, an evolutionary conserved Brain Specific homeoboX gene expressed in the septum, epiphysis, mammillary bodies and arcuate nucleus
2003
·
Mattia Cremona
, Elena Colombo
, et al.
·
Gene Expression Patterns
·
34
Proteomics study of medullary thyroid carcinomas expressing RET germ‐line mutations: Identification of new signaling elements
2008
·
L. Gorla
, P. Mondellini
, et al.
·
Molecular Carcinogenesis
·
32
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
2023
·
Cha Len Lee
, Mattia Cremona
, et al.
·
Cancer Biology & Therapy
·
30
PDF
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
2016
·
Manuela Salvucci
, Maximilian L. Würstle
, et al.
·
Clinical Cancer Research
·
27
Elevated levels of the acute‐phase serum amyloid are associated with heightened lung cancer risk
2010
·
Mattia Cremona
, Elisa Calabrò
, et al.
·
Cancer
·
26
PDF
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
2018
·
Ozlem Aslan
, Mattia Cremona
, et al.
·
BMC Cancer
·
25
PDF
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
2017
·
John O’Shea
, Mattia Cremona
, et al.
·
Oncotarget
·
25
PDF
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
2018
·
Damien Coté
, Alex Eustace
, et al.
·
PLoS ONE
·
24
PDF
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
2020
·
Laura Breen
, Patricia B. Gaule
, et al.
·
Investigational New Drugs
·
19
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
2016
·
Sinead Toomey
, Stephen F. Madden
, et al.
·
Oncotarget
·
19
PDF
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
2022
·
Mattia Cremona
, Cassandra J. Vandenberg
, et al.
·
British Journal of Cancer
·
18
PDF
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
2020
·
Sinead Toomey
, Aoife Carr
, et al.
·
Journal of Translational Medicine
·
18
PDF
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
2018
·
Malgorzata Milewska
, Mattia Cremona
, et al.
·
Therapeutic Advances in Medical Oncology
·
15
RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
2023
·
Cathy Richards
, Yasir Elamin
, et al.
·
International Journal of Molecular Sciences
·
14
PDF
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
2018
·
Naomi Elster
, Sinead Toomey
, et al.
·
Therapeutic Advances in Medical Oncology
·
14
Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression
2022
·
Yvonne E. Smith
, Guannan Wang
, et al.
·
Cancers
·
12
PDF
Systems analysis of protein signatures predicting cetuximab responses in KRAS , NRAS , BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer
2020
·
Andreas U. Lindner
, Steven Carberry
, et al.
·
International Journal of Cancer
·
12
PDF
Stratification of clear cell renal cell carcinoma by signaling pathway analysis
2014
·
Mattia Cremona
, Virginia Espina
, et al.
·
Expert Review of Proteomics
·
12
Show more works
View as search
Works count:
97
Citation count:
1,215
H-index:
18
I10-index:
30
Year
Topic
Type